.Nature Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view calls for addition of patients along with MASLD as well as measurement of liver end results in cardio-- kidney-- metabolic trials, when information propose mechanistically probable benefits as well as clinical safety-- and also summarizes factors to consider for trial concept as well as regulatory approval.